5d 1m 3m 1y 5y 10y
Poniard Pharmaceuticals: Platinum Rediscovered (Part I)Ohad Hammer • May. 30, 2008
PARD vs. ETF Alternatives
Wednesday, Feb 32010, 2:16 PMShares of Poniard Pharmaceuticals (PARD) -8.8% after the firm said it's replacing its CEO and cutting its work force by 57%. Moves come after disappointing results last week from a Phase II trial of its cancer drug picoplatin. Shares are down 76% over the past three months. |Wednesday, Feb 32010, 2:16 PM| Comment!
Thursday, May 282009, 9:02 AM